Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 648 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CMO Rebecca Taub sold 648 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $217,235.52. Following the completion of the transaction, the chief marketing officer now directly owns 456,662 shares of the company's stock, valued at approximately $153,091,368.88. This represents a 0.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Rebecca Taub also recently made the following trade(s):

• On Friday, January 17th, Rebecca Taub sold 1,689 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $273.41, for a total transaction of $461,789.49.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL traded down $17.22 during mid-day trading on Monday, hitting $310.92. 558,393 shares of the company traded hands, compared to its average volume of 502,950. The stock's fifty day moving average price is $314.37 and its 200-day moving average price is $273.95. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals, Inc. has a one year low of $168.25 and a one year high of $368.29. The firm has a market cap of $6.78 billion, a price-to-earnings ratio of -12.40 and a beta of -0.36.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.94) by $2.02. The company had revenue of $62.18 million during the quarter, compared to the consensus estimate of $34.60 million. During the same quarter in the prior year, the firm posted ($5.34) earnings per share. Research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. JMP Securities reiterated a "market outperform" rating and set a $427.00 price target on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. StockNews.com upgraded Madrigal Pharmaceuticals to a "sell" rating in a research note on Saturday, October 12th. Cantor Fitzgerald restated a "neutral" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. HC Wainwright increased their price objective on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a "buy" rating in a research report on Tuesday, January 14th. Finally, Oppenheimer decreased their target price on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an "outperform" rating for the company in a research report on Wednesday, October 23rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Madrigal Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $351.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MDGL. Nisa Investment Advisors LLC increased its stake in Madrigal Pharmaceuticals by 47.6% during the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 68 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Madrigal Pharmaceuticals by 172.8% in the 3rd quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company's stock valued at $123,000 after purchasing an additional 368 shares during the last quarter. Centaurus Financial Inc. purchased a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter worth approximately $163,000. Amalgamated Bank increased its position in shares of Madrigal Pharmaceuticals by 20.2% during the 2nd quarter. Amalgamated Bank now owns 607 shares of the biopharmaceutical company's stock valued at $170,000 after purchasing an additional 102 shares during the last quarter. Finally, KBC Group NV raised its holdings in Madrigal Pharmaceuticals by 73.5% during the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company's stock valued at $188,000 after buying an additional 258 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.